Finch Therapeutics Group, Inc. Common Stock
FNCH
FNCH was delisted on the 24th of May, 2024.
44 hedge funds and large institutions have $107M invested in Finch Therapeutics Group, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 6 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
38% more capital invested
Capital invested by funds: $77.2M → $107M (+$29.6M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 45 → 44 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.2M |
| 2 |
LSAG
Lake Street Advisors Group
Portsmouth,
New Hampshire
|
+$9.04M |
| 3 |
LSCM
Light Street Capital Management
Palo Alto,
California
|
+$8.94M |
| 4 |
MP
MSD Partners
New York
|
+$2.18M |
| 5 |
BP
Ballentine Partners
Waltham,
Massachusetts
|
+$2.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.23M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.61M |
| 3 |
AI
Aperture Investors
New York
|
-$1.24M |
| 4 |
PVI
Pura Vida Investments
New York
|
-$1.01M |
| 5 |
Millennium Management
New York
|
-$917K |
FNCH Hedge Fund Activity: Q3 2021 in Review
44 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Finch Therapeutics Group, Inc. Common Stock (FNCH) for Q3 2021, worth a combined $107M — up 38% from $77.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of FNCH and 5 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 19 added.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $25.2M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.23M sold.
- 44 institutional investors held Finch Therapeutics Group, Inc. Common Stock (FNCH) as of Q3 2021, down from 45 in Q2 2021.
- Funds reported $107M of Finch Therapeutics Group, Inc. Common Stock stock for Q3 2021, up 38% quarter-over-quarter.
- 5 funds opened new Finch Therapeutics Group, Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of -1 holder.
- The largest Finch Therapeutics Group, Inc. Common Stock buyer in Q3 2021 was Susquehanna International Group, an estimated $25.2M added.
- The largest Finch Therapeutics Group, Inc. Common Stock seller in Q3 2021 was Sectoral Asset Management, an estimated $4.23M sold.
Based on aggregated 13F filings for Q3 2021.